ADAPTIR Modular Protein Therapeutic Platform

Oncology candidates

Name
Pre-clinical
Phase 1
Phase 2
Phase 3
 
 
 
Otlertuzumab, originally known as TRU-016 (anti-CD37)
Pre-clinical Phase 1 Phase 2 Phase 3
MOR209/ES414 (anti-PSMA x anti-CD3)
Pre-clinical Phase 1 Phase 2 Phase 3
APVO425 (anti-ROR1 x anti-CD3)
Pre-clinical Phase 1 Phase 2 Phase 3
Additional RTCC assets (targets not disclosed)
Pre-clinical Phase 1 Phase 2 Phase 3